The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Defibrillators, Implantable

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Defibrillators, Implantable


High impact information on Defibrillators, Implantable


Chemical compound and disease context of Defibrillators, Implantable


Biological context of Defibrillators, Implantable


Anatomical context of Defibrillators, Implantable


Associations of Defibrillators, Implantable with chemical compounds


Gene context of Defibrillators, Implantable


Analytical, diagnostic and therapeutic context of Defibrillators, Implantable


  1. The role of the implantable cardioverter-defibrillator for prevention of sudden cardiac death. Josephson, M.E., Callans, D.J., Buxton, A.E. Ann. Intern. Med. (2000) [Pubmed]
  2. Design and results of the antiarrhythmics vs implantable defibrillators (AVID) registry. The AVID Investigators. Anderson, J.L., Hallstrom, A.P., Epstein, A.E., Pinski, S.L., Rosenberg, Y., Nora, M.O., Chilson, D., Cannom, D.S., Moore, R. Circulation (1999) [Pubmed]
  3. Morning peak in ventricular tachyarrhythmias detected by time of implantable cardioverter/defibrillator therapy. The CPI Investigators. Tofler, G.H., Gebara, O.C., Mittleman, M.A., Taylor, P., Siegel, W., Venditti, F.J., Rasmussen, C.A., Muller, J.E. Circulation (1995) [Pubmed]
  4. Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Böcker, D., Haverkamp, W., Block, M., Borggrefe, M., Hammel, D., Breithardt, G. Circulation (1996) [Pubmed]
  5. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. Knight, B.P., Goyal, R., Pelosi, F., Flemming, M., Horwood, L., Morady, F., Strickberger, S.A. J. Am. Coll. Cardiol. (1999) [Pubmed]
  6. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy. Raj, S.R., Mitchell, L.B., Sheldon, R.S. N. Engl. J. Med. (2000) [Pubmed]
  7. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. Pacifico, A., Hohnloser, S.H., Williams, J.H., Tao, B., Saksena, S., Henry, P.D., Prystowsky, E.N. N. Engl. J. Med. (1999) [Pubmed]
  8. Recurrent cardiac events in survivors of ventricular fibrillation or tachycardia. Implications for driving restrictions. Larsen, G.C., Stupey, M.R., Walance, C.G., Griffith, K.K., Cutler, J.E., Kron, J., McAnulty, J.H. JAMA (1994) [Pubmed]
  9. Driving and the implantable cardioverter defibrillator. Study Group on ICD and Driving. Jung, W., Lüderitz, B. Lancet (1996) [Pubmed]
  10. "Stable" ventricular tachycardia is not a benign rhythm : insights from the antiarrhythmics versus implantable defibrillators (AVID) registry. Raitt, M.H., Renfroe, E.G., Epstein, A.E., McAnulty, J.H., Mounsey, P., Steinberg, J.S., Lancaster, S.E., Jadonath, R.L., Hallstrom, A.P. Circulation (2001) [Pubmed]
  11. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. Strickberger, S.A., Hummel, J.D., Bartlett, T.G., Frumin, H.I., Schuger, C.D., Beau, S.L., Bitar, C., Morady, F. J. Am. Coll. Cardiol. (2003) [Pubmed]
  12. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators. Stevens, S.K., Haffajee, C.I., Naccarelli, G.V., Schwartz, K.M., Luceri, R.M., Packer, D.L., Rubin, A.M., Kowey, P.R. J. Am. Coll. Cardiol. (1996) [Pubmed]
  13. Cardiac release of histamine after ventricular fibrillation and defibrillation during insertion of implantable cardioverter defibrillators (ICD). Valen, G., Runsiö, M., Owall, A., Kaszaki, J., Nagy, S., Rosenqvist, M., Bergfeldt, L., Vaage, J. Inflamm. Res. (1995) [Pubmed]
  14. Serum creatine kinase activity and sensing characteristics after intraoperative arrhythmia induction using implantable defibrillator rate sensing leads. Grubb, B.P., Durzinsky, D., Mancini, M.C., Temesy-Armos, P. Pacing and clinical electrophysiology : PACE. (1992) [Pubmed]
  15. Brief review of the recently described short QT syndrome and other cardiac channelopathies. Pérez Riera, A.R., Ferreira, C., Dubner, S.J., Schapachnik, E., Soares, J.D., Francis, J. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc. (2005) [Pubmed]
  16. Survival analysis and clinical medicine. An observational comparison of the implantable cardioverter defibrillator, amiodarone treatment, and heart transplantation. Ector, H., Jordaens, L., Vanhaecke, J. Eur. Heart J. (1996) [Pubmed]
  17. Fractal correlation properties of heart rate dynamics and adverse events in patients with implantable cardioverter-defibrillators. Perkiömäki, J.S., Zareba, W., Daubert, J.P., Couderc, J.P., Corsello, A., Kremer, K. Am. J. Cardiol. (2001) [Pubmed]
  18. Recent primary prevention implantable cardioverter defibrillator trials. Duray, G., Israel, C.W., Hohnloser, S.H. Current opinion in cardiology. (2006) [Pubmed]
  19. Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function. Schaer, B.A., Ammann, P., Sticherling, C., Zellweger, M.J., Cron, T.A., Osswald, S. International journal of cardiology. (2006) [Pubmed]
  20. Early cardioverter defibrillator infection: value of indium-111 leukocyte imaging. Bhadelia, R.A., Oates, E. Ann. Thorac. Surg. (1997) [Pubmed]
  21. Hypertrophic obstructive cardiomyopathy in pediatric patients: results of surgical treatment. Theodoro, D.A., Danielson, G.K., Feldt, R.H., Anderson, B.J. J. Thorac. Cardiovasc. Surg. (1996) [Pubmed]
  22. Iontophoretic transmyocardial drug delivery. A novel approach to antiarrhythmic drug therapy. Avitall, B., Hare, J., Zander, G., Bockoff, C., Tchou, P., Jazayeri, M., Akhtar, M. Circulation (1992) [Pubmed]
  23. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. Singer, I., Al-Khalidi, H., Niazi, I., Tchou, P., Simmons, T., Henthorn, R., Holroyde, M., Brum, J. J. Am. Coll. Cardiol. (2004) [Pubmed]
  24. Lessons learned from data logging in a multicenter clinical trial using a late-generation implantable cardioverter-defibrillator. The Guardian ATP 4210 Multicenter Investigators Group. Wood, M.A., Stambler, B.S., Damiano, R.J., Greenway, P., Ellenbogen, K.A. J. Am. Coll. Cardiol. (1994) [Pubmed]
  25. A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. Michaud, G.F., Pelosi, F., Noble, M.D., Knight, B.P., Morady, F., Strickberger, S.A. J. Am. Coll. Cardiol. (2000) [Pubmed]
  26. Mutational screening of SCN5A linked disorders in Polish patients and their family members. Moric-Janiszewska, E., Herbert, E., Cholewa, K., Filipecki, A., Trusz-Gluza, M., Wilczok, T. J. Appl. Genet. (2004) [Pubmed]
  27. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). Hodgkinson, K.A., Parfrey, P.S., Bassett, A.S., Kupprion, C., Drenckhahn, J., Norman, M.W., Thierfelder, L., Stuckless, S.N., Dicks, E.L., McKenna, W.J., Connors, S.P. J. Am. Coll. Cardiol. (2005) [Pubmed]
  28. Molecular biology of sodium channels and their role in cardiac arrhythmias. Grant, A.O. Am. J. Med. (2001) [Pubmed]
  29. Advanced rhythm discrimination for implantable cardioverter defibrillators using electrogram vector timing and correlation. Gold, M.R., Shorofsky, S.R., Thompson, J.A., Kim, J., Schwartz, M., Bocek, J., Lovett, E.G., Hsu, W., Morris, M.M., Lang, D.J. J. Cardiovasc. Electrophysiol. (2002) [Pubmed]
  30. Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Roguin, A., Bomma, C.S., Nasir, K., Tandri, H., Tichnell, C., James, C., Rutberg, J., Crosson, J., Spevak, P.J., Berger, R.D., Halperin, H.R., Calkins, H. J. Am. Coll. Cardiol. (2004) [Pubmed]
  31. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. Rosenqvist, M., Beyer, T., Block, M., den Dulk, K., Minten, J., Lindemans, F. Circulation (1998) [Pubmed]
  32. Navigation in the mega-trials waters: reflections on the Multicenter Automatic Defibrillator Implantation Trial and the Antiarrhythmics Versus Implantable Defibrillators Study. Farré, J. Am. J. Cardiol. (1999) [Pubmed]
  33. Acute effects of intravenous propafenone on the internal ventricular defibrillation threshold in the anesthetized dog. Peters, W., Gang, E.S., Okazaki, H., Solingen, S., Kobayashi, Y., Karagueuzian, H.S., Mandel, W.J. Am. Heart J. (1991) [Pubmed]
  34. Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE trial). Cardiac Arrest in Seattle, Conventional versus Amiodarone Drug Evaluation. Dolack, G.L. Am. J. Cardiol. (1994) [Pubmed]
  35. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy. Singh, B.N. Am. J. Cardiol. (1993) [Pubmed]
WikiGenes - Universities